Patents by Inventor Narendra K. Vaish
Narendra K. Vaish has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240360445Abstract: Inhibitory RNA molecules that specifically inhibit mammalian RIZ2 expression, with therapeutic effect in cell proliferative diseases, such as cancer.Type: ApplicationFiled: April 23, 2024Publication date: October 31, 2024Inventors: Lonnie L. BOOKBINDER, Narendra K. VAISH, Brad J. NILES, Jonathan FLYNN, Nicole NUNEZ
-
Patent number: 12012597Abstract: Inhibitory RNA molecules that specifically inhibit mammalian RIZ2 expression, with therapeutic effect in cell proliferative diseases, such as cancer.Type: GrantFiled: September 15, 2022Date of Patent: June 18, 2024Assignee: ARIZ Precision Medicine, Inc.Inventors: Lonnie L. Bookbinder, Narendra K. Vaish, Brad J. Niles, Jonathan Flynn, Nicole Nunez
-
Publication number: 20230099879Abstract: Inhibitory RNA molecules that specifically inhibit mammalian RIZ2 expression, with therapeutic effect in cell proliferative diseases, such as cancer.Type: ApplicationFiled: September 15, 2022Publication date: March 30, 2023Inventors: Lonnie L. BOOKBINDER, Narendra K. VAISH, Brad J. NILES, Jonathan FLYNN, Nicole NUNEZ
-
Publication number: 20220267775Abstract: Pharmaceutical formulations for the treatment of cancer comprising novel siRNAs that downregulate expression of the PRDM oncoprotein gene and inhibit tumor growth. siRNAs designed and selected to destroy PRDM14 mRNA are described. The siRNAs are delivered via one or more targeted drug delivery systems equipped with a tumor-specific targeting ligand that confers specific binding of the nanoparticle with siRNA payload to receptors on the surface of tumor cells.Type: ApplicationFiled: January 7, 2022Publication date: August 25, 2022Inventors: Lonnie L. BOOKBINDER, Brad NILE, Nicole NUNEZ, Nicole HALMAI, Narendra K. VAISH
-
Patent number: 10023863Abstract: This invention provides single-stranded and multi-stranded compounds that are useful in various therapeutic modalities to regulate the expression of nucleic acid molecules in a cell. A range of compounds is provided, each containing one or more conformationally restricted nucleomonomers (CRN). In addition, compounds can contain one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (unlocked nucleomonomers, UNA).Type: GrantFiled: February 17, 2015Date of Patent: July 17, 2018Assignee: Marina Biotech, Inc.Inventors: Michael V. Templin, Narendra K. Vaish, Kathy L. Fosnaugh, Shaguna Seth, Michael E. Houston, Jr.
-
Publication number: 20160215293Abstract: This invention provides oligomer structures for therapeutic agents, the oligomers composed of one or more UNA nucleomonomers, along with nucleic acid monomers. The UNA oligomers may be used as therapeutic agents for treating or preventing disease. The UNA oligomers can be capable of modulating or silencing gene expression, through RNA interference or other modalities, and may have an antisense strand and a sense strand.Type: ApplicationFiled: April 12, 2016Publication date: July 28, 2016Inventors: Michael V. Templin, Narendra K. Vaish, Barry A. Polisky, Michael E. Houston, JR.
-
Patent number: 9340789Abstract: This disclosure provides double-stranded RNA complexes having one or more hydroxymethyl substituted nucleomonomer(s) in the passenger strand (or sense strand) of an RNA complex. RNA complexes of the disclosure may be useful for therapeutic applications, diagnostic applications or research applications. RNA complexes include short interfering RNA complexes (siRNA) capable of modulating gene expression comprising an antisense strand and a continuous or a discontinuous passenger strand (“sense strand”). Further, one or more hydroxymethyl substituted nucleomonomer(s) of this disclosure may be positioned at the 3?-end, at the 5?-end, at both the 3?-end and 5?end.Type: GrantFiled: December 3, 2009Date of Patent: May 17, 2016Assignee: Arcturus Therapeutics, Inc.Inventors: Michael V. Templin, Narendra K. Vaish, Barry A. Polisky, Michael E. Houston, Jr.
-
Publication number: 20150315591Abstract: The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.Type: ApplicationFiled: May 28, 2015Publication date: November 5, 2015Applicant: MARINA BIOTECH, INC.Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
-
Publication number: 20150284717Abstract: This invention provides single-stranded and multi-stranded compounds that are useful in various therapeutic modalities to regulate the expression of nucleic acid molecules in a cell. A range of compounds is provided, each containing one or more conformationally restricted nucleomonomers (CRN). In addition, compounds can contain one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (unlocked nucleomonomers, UNA).Type: ApplicationFiled: February 17, 2015Publication date: October 8, 2015Inventors: Michael V. Templin, Narendra K. Vaish, Kathy L. Fosnaugh, Shaguna Seth, Michael E. Houston, JR.
-
Publication number: 20150258130Abstract: The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.Type: ApplicationFiled: May 27, 2015Publication date: September 17, 2015Applicant: MARINA BIOTECH, INC.Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
-
Publication number: 20150259686Abstract: The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.Type: ApplicationFiled: May 28, 2015Publication date: September 17, 2015Applicant: MARINA BIOTECH, INC.Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
-
Patent number: 9074205Abstract: The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.Type: GrantFiled: October 18, 2007Date of Patent: July 7, 2015Assignee: Marina Biotech, Inc.Inventors: Steven C. Quay, James Mcswiggen, Narendra K. Vaish, Mohammad Ahmadian
-
Publication number: 20150105445Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.Type: ApplicationFiled: August 13, 2014Publication date: April 16, 2015Applicant: SIRNA THERAPEUTICS, INC.Inventors: James McSwiggen, Bharat Chowrira, Leonid Beigelman, Dennis Macejak, Shawn Zinnen, Pamela Pavco, Peter Haeberli, David Morrissey, Kathy Fosnaugh, Sharon F. Jamison, Nassim Usman, James Thompson, Chandra Vargeese, Weimin Wang, Tongqian Chen, Narendra K. Vaish
-
Patent number: 8846894Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.Type: GrantFiled: February 16, 2007Date of Patent: September 30, 2014Assignee: Sirna Therapeutics, Inc.Inventors: James McSwiggen, Bharat Chowrira, Leonid Beigelman, Dennis Macejak, Shawn Zinnen, Pamela Pavco, Peter Haeberli, David Morrissey, Kathy Fosnaugh, Sharon F Jamison, Nassim Usman, James Thompson, Chandra Vargeese, Weimin Wang, Tongqian Chen, Narendra K Vaish
-
Publication number: 20130190383Abstract: This disclosure provides single-stranded and multi-stranded nucleic acid compounds having one or more double-stranded regions that regulate the function or expression of nucleic acid molecules expressed in a cell or a cell regulatory system dependent upon a nucleic acid. The disclosure provides a range of nucleic acid compounds having one or more conformationally restricted nucleomonomers (CRN). Certain nucleic acid compounds may have one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (UNA). The nucleic acid compounds are useful in various therapeutic modalities.Type: ApplicationFiled: April 26, 2011Publication date: July 25, 2013Applicant: MARINA BIOTECH, INC.Inventors: Narendra K. Vaish, Kathy L. Fosnaugh, Shaguna Seth, Michael E. Houston, JR., Michael V. Templin
-
Publication number: 20130011922Abstract: The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), and blunt ended double-stranded ribonucleic acid molecules capable of decreasing or silencing expression of a target gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target mRNA. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease or condition associated with the target gene.Type: ApplicationFiled: December 15, 2011Publication date: January 10, 2013Applicants: F/K/A MDRNA, INC., MARINA BIOTECH, INC.Inventors: STEVEN C. QUAY, JAMES MCSWIGGEN, NARENDRA K. VAISH, MOHAMMAD AHMADIAN
-
Publication number: 20110313020Abstract: This disclosure provides double-stranded RNA complexes having one or more hydroxymethyl substituted nucleomonomer(s) in the passenger strand (or sense strand) of an RNA complex. RNA complexes of the disclosure may be useful for therapeutic applications, diagnostic applications or research applications. RNA complexes include short interfering RNA complexes (siRNA) capable of modulating gene expression comprising an antisense strand and a continuous or a discontinuous passenger strand (“sense strand”). Further, one or more hydroxymethyl substituted nucleomonomer(s) of this disclosure may be positioned at the 3?-end, at the 5?-end, at both the 3?-end and 5?end.Type: ApplicationFiled: December 3, 2009Publication date: December 22, 2011Applicant: MARINA BIOTECH, INC.Inventors: Michael V. Templin, Narendra K. Vaish, Barry A. Polisky, Michael E. Houston, Jr.
-
Publication number: 20110236972Abstract: The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), capable of decreasing or silencing BIRC5 gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a BIRC5 mRNA. Also provided are methods of decreasing expression of a BIRC5 gene in a cell or in a subject to treat a BIRC5-related disease.Type: ApplicationFiled: August 5, 2009Publication date: September 29, 2011Applicant: MARINA BIOTECH, INC.Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Kathy L. Fosnaugh, Shaguna Seth
-
Publication number: 20110136233Abstract: The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), capable of decreasing or silencing gene expression of PLK1 gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a PLK1 mRNA. Also provided are methods of decreasing expression of a PLK1 gene in a cell or in a subject to treat a PLK family member-related disease.Type: ApplicationFiled: August 5, 2009Publication date: June 9, 2011Applicant: MARINA BIOTECH, INC.Inventors: Steven C. Quay, Narendra K. Vaish, Kathy L. Fosnaugh, Shaguna Seth
-
Publication number: 20100209487Abstract: The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.Type: ApplicationFiled: October 18, 2007Publication date: August 19, 2010Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Steven C. Quay, James Mcswiggen, Narendra K. Vaish, Mohammad Ahmadian